Molecular Pharmacology of ABCG2 and its role in chemoresistance

Molecular Pharmacology

Volumn 84, Issue 5, 2013, Pages 655-669

  Stacy, Alexandra E ^a   Jansson, Patric J ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; ADENOSINE TRIPHOSPHATASE; ANTHRACYCLINE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CIMETIDINE; CYCLOSPORIN A; DAUNORUBICIN; DIFLOMOTECAN; DOXORUBICIN; ELACRIDAR; FIRTECAN; FLAVOPIRIDOL; FUMITREMORGIN C; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTOPORPHYRIN; SILDENAFIL; TARIQUIDAR; TOPOTECAN; UNINDEXED DRUG; ZIDOVUDINE;

BLOOD BRAIN BARRIER; BLOOD TESTIS BARRIER; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELLULAR DISTRIBUTION; CHROMOSOMAL LOCALIZATION; COMPUTER PREDICTION; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; ENZYME SPECIFICITY; ESTROGEN RESPONSIVE ELEMENT; GASTROINTESTINAL TRACT; GENE CONTROL; GENE EXPRESSION; GENE STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; MAMMARY GLAND; MULTIDRUG RESISTANCE; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION SITE; URINARY EXCRETION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84885972386     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088609     Document Type: Review

References (172)

1. Abbott BL, Colapietro A-M, Barnes Y, Marini F, Andreeff M, and Sorrentino BP (2002) Low levels of ABCG2 expression in adult AML blast samples. Blood 100:4594-4601. (Pubitemid 35429703)
2. Adeoya-Osiguwa SA, Markoulaki S, Pocock V, Milligan SR, and Fraser LR (2003) 17β-Estradiol and environmental estrogens significantly affect mammalian sperm function. Hum Reprod 18:100-107. (Pubitemid 36138859)
3. Ahmed-Belkacem A, Macalou S, Borrelli F, Capasso R, Fattorusso E, Taglialatela-Scafati O, and Di Pietro A (2007) Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J Med Chem 50:1933-1938. (Pubitemid 46626602)
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, and Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
5. Allen JD, Jackson SC, and Schinkel AH (2002a) A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62:2294-2299. (Pubitemid 34411707)
6. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens J H M, Koomen GJ, and Schinkel AH (2002b) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425.
7. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, and Urbatsch IL et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
8. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, and Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339. (Pubitemid 28551112)
9. An R, Hagiya Y, Tamura A, Li S, Saito H, Tokushima D, and Ishikawa T (2009) Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res 26:449-458.
10. An Y and Ongkeko WM (2009) ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5:1529-1542.
11. Aust S, Obrist P, Jaeger W, Klimpfinger M, Tucek G, Wrba F, Penner E, and Thalhammer T (2004) Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab Invest 84:1024-1036. (Pubitemid 39025037)
12. Bailey-Dell KJ, Hassel B, Doyle LA, and Ross DD (2001) Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520:234-241. (Pubitemid 32868794)
13. Bart J, Hollema H, Groen HJ, De Vries EG, Hendrikse NH, Sleijfer DT, Wegman TD, Vaalburg W, and van der Graaf WT (2004) The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40:2064-2070. (Pubitemid 39165539)
14. Benderra Z, Faussat A-M, Sayada L, Perrot J-Y, Chaoui D, Marie J-P, and Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896-7902. (Pubitemid 39587528)
15. Benderra Z, Faussat AM, Sayada L, Perrot J-Y, Tang R, Chaoui D, Morjani H, Marzac C, Marie J-P, and Legrand O (2005) MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11:7764-7772. (Pubitemid 41611620)
16. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, Ko MK, Bayan J-A, Sacapano MR, and Espinoza A et al. (2008) PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 1230:290-302.
17. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
18. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, and Nooter K (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9:827-836. (Pubitemid 36182621)
19. Cai X, Bikadi Z, Ni Z, Lee E-W, Wang H, Rosenberg MF, and Mao Q (2010) Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport. J Pharmacol Exp Ther 333:670-681.
20. Chen J, Lu G, Lin J, Davidson AL, and Quiocho FA (2003a) A tweezers-like motion of the ATP-binding cassette dimer in an ABC transport cycle. Mol Cell 12:651-661. (Pubitemid 37222486)
21. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang JL, and Fojo AT (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073-10080.
22. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD (2003b) Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054. (Pubitemid 36917926)
23. Chu TS, Chen JS, Lopez JP, Pardo FS, Aguilera J, and Ongkeko WM (2008) Imatinibmediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 134:979-984.
24. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654. (Pubitemid 23012438)
25. Cortez MA, Scrideli CA, Yunes JA, Valera ET, Toledo SR, Pavoni-Ferreira PC, Lee ML, Petrilli AS, Brandalise SR, and Tone LG (2009) mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatr Blood Cancer 53:996-1004.
26. Cramer J, Kopp S, Bates SE, Chiba P, and Ecker GF (2007) Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem 2:1783-1788.
27. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, and Sparreboom A et al. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739-1742. (Pubitemid 44942712)
28. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, and Dent P et al. (2010) Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA 107:18202-18207.
29. Dawson RJ and Locher KP (2006) Structure of a bacterial multidrug ABC transporter. Nature 443:180-185. (Pubitemid 44387602)
30. Dean M, Fojo T, and Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284. (Pubitemid 40488633)
31. De Bruin M, Miyake K, Litman T, Robey R, and Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126. (Pubitemid 29492880)
32. De Figueiredo-Pontes LL, Pintão M C T, Oliveira LC, Dalmazzo LF, Jácomo RH, Garcia AB, Falcão RP, and Rego EM (2008) Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom 74:163-168. (Pubitemid 351656296)
33. De Jong FA, Marsh S, Mathijssen R H J, King C, Verweij J, Sparreboom A, and McLeod HL (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894. (Pubitemid 39180970)
34. Diestra JE, Scheffer GL, Català I, Maliepaard M, Schellens JH, Scheper RJ, Germà-Lluch JR, and Izquierdo MA (2002) Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198:213-219. (Pubitemid 35243879)
35. Diop NK and Hrycyna CA (2005) N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 44:5420-5429. (Pubitemid 40489981)
36. Doyle LA and Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358. (Pubitemid 37487163)
37. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670. (Pubitemid 29018757)
38. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, and Beck WT (2004) Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64:1247-1251. (Pubitemid 38235590)
39. Eisenblätter T, Hüwel S, and Galla H-J (2003) Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 971:221-231. (Pubitemid 36423323)
40. Elkind NB, Szentpétery Z, Apáti Á, Özvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, and Buday L et al. (2005) Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65:1770-1777. (Pubitemid 40478603)
41. Enokizono J, Kusuhara H, and Sugiyama Y (2007) Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72:967-975. (Pubitemid 47481419)
42. Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH, and van De Vijver MJ (2002) Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 8:1068-1074. (Pubitemid 35177357)
43. Fojo AT, Shen DW, Mickley LA, Pastan I, and Gottesman MM (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5:1922-1927. (Pubitemid 18010151)
44. Foraker AB, Khantwal CM, and Swaan PW (2003) Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev 55:1467-1483. (Pubitemid 37464573)
45. Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, and Petrini M (2004) Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res 28:367-372. (Pubitemid 38199944)
46. Gedeon C, Anger G, Piquette-Miller M, and Koren G (2008) Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta 29:39-43.
47. Giri N, Agarwal S, Shaik N, Pan G, Chen Y, and Elmquist WF (2009) Substratedependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 37:560-570.
48. Gödecke A, Flögel U, Zanger K, Ding Z, Hirchenhain J, Decking UK, and Schrader J (1999) Disruption of myoglobin in mice induces multiple compensatory mechanisms. Proc Natl Acad Sci USA 96:10495-10500. (Pubitemid 29422587)
49. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58. (Pubitemid 37328807)
50. Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, and Hobbs HH (2003) ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 278:48275-48282. (Pubitemid 37523283)
51. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, and Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374-383. (Pubitemid 43800742)
52. Gutmann H, Hruz P, Zimmermann C, Beglinger C, and Drewe J (2005) Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 70:695-699. (Pubitemid 41058704)
53. Henriksen U, Fog JU, Litman T, and Gether U (2005) Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem 280:36926-36934. (Pubitemid 41587775)
54. Hillebrand M, Verrier SE, Ohlenbusch A, Schäfer A, Söling H-D, Wouters FS, and Gärtner J (2007) Live cell FRET microscopy: homo- and heterodimerization of two human peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP, ABCD1) and PMP70 (ABCD3). J Biol Chem 282:26997-27005. (Pubitemid 47501958)
55. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807. (Pubitemid 41206035)
56. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, and Brenner MK (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228-14233. (Pubitemid 39305058)
57. Hogue DL, Liu L, and Ling V (1999) Identification and characterization of a mammalian mitochondrial ATP-binding cassette membrane protein. J Mol Biol 285:379-389. (Pubitemid 29034051)
58. Honjo Y, Hrycyna CA, Yan Q-W, Medina-Pérez WY, Robey RW, van De Laar A, Litman T, Dean M, and Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-6639. (Pubitemid 32896477)
59. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, and Traxler P (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333-2337. (Pubitemid 38523883)
60. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
61. Huls M, Brown CD, Windass AS, Sayer R, Van Den Heuvel JJ, Heemskerk S, Russel FG, and Masereeuw R (2008) The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73:220-225.
62. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, and Sugimoto Y (2003) Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64:610-618. (Pubitemid 37048564)
63. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, and van Veen HW (2003) Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 278:20645-20651. (Pubitemid 36806364)
64. Jonker JW, Buitelaar M, Wagenaar E, Van der Valk MA, Scheffer GL, Scheper RJ, Plösch T, Kuipers F, Elferink R P J, and Rosing H et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654. (Pubitemid 35403986)
65. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129. (Pubitemid 40321346)
66. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
67. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
68. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, and Sugimoto Y (2002) Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97:626-630. (Pubitemid 34087801)
69. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, and Takebayashi Y (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92:452-458. (Pubitemid 32427782)
70. Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, and Ochiai A (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105-111.
71. Kleijmeer MJ, Kelly A, Geuze HJ, Slot JW, Townsend A, and Trowsdale J (1992) Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature 357:342-344.
72. Knutsen T, Rao VK, Ried T, Mickley L, Schneider E, Miyake K, Ghadimi BM, Padilla-Nash H, Pack S, and Greenberger L et al. (2000) Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer 27:110-116.
73. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, and Terakawa N et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94-101. (Pubitemid 40023519)
74. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
75. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, and Schuetz JD (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218-24225. (Pubitemid 38725283)
76. Langosch D, Brosig B, Kolmar H, and Fritz H-J (1996) Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator. J Mol Biol 263:525-530. (Pubitemid 26382072)
77. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, and Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648. (Pubitemid 24067706)
78. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, and Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323-3329.
79. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237. (Pubitemid 40552845)
80. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, and Baker SD (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432-438. (Pubitemid 47328313)
81. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011-2021. (Pubitemid 30386505)
82. Litman T, Jensen U, Hansen A, Covitz K-M, Zhan Z, Fetsch P, Abati A, Hansen PR, Horn T, and Skovsgaard T et al. (2002) Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim Biophys Acta 1565:6-16. (Pubitemid 35239827)
83. Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, and Oseroff AR (2007) The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 13:2463-2470. (Pubitemid 46698598)
84. Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, and Schellens JH (1998) Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 77:1645-1652. (Pubitemid 28230467)
85. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001a) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464. (Pubitemid 32695041)
86. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, De Jong LA, Pluim D, Beijnen JH, and Schellens JH (2001b) Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7:935-941. (Pubitemid 32708732)
87. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, Ford RC, and Callaghan R (2006) Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14:1623-1632. (Pubitemid 46107268)
88. Merino G, Álvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
89. Misra S, Ujházy P, Gatmaitan Z, Varticovski L, and Arias IM (1998) The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver. J Biol Chem 273:26638-26644. (Pubitemid 28471677)
90. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, and Sugimoto Y (2003) Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer 107:757-763. (Pubitemid 37339729)
91. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, and Fojo T et al. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13. (Pubitemid 29062946)
92. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246. (Pubitemid 38240926)
93. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, and Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5, 7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 32:898-901. (Pubitemid 39096047)
94. Mo W and Zhang J-T (2012) Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3:1-27.
95. Morisaki K, Robey RW, Özvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172. (Pubitemid 40884271)
96. Myllynen P, Kummu M, Kangas T, Ilves M, Immonen E, Rysä J, Pirilä R, Lastumäki A, and Vähäkangas KH (2008) ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6- phenylimidazo[4, 5-b]pyridine (PhIP) in perfused term human placenta. Toxicol Appl Pharmacol 232:210-217.
97. Nakanishi T, Shiozawa K, Hassel BA, and Ross DD (2006) Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108:678-684. (Pubitemid 44061370)
98. Natarajan K, Xie Y, Baer MR, and Ross DD (2012) Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83:1084-1103.
99. Ni Z, Bikadi Z, Rosenberg MF, and Mao Q (2010a) Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 11:603-617.
100. Ni Z, Mark ME, Cai X, and Mao Q (2010b) Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. Int J Biochem Mol Biol 1:1-11.
101. Nobili S, Landini I, Giglioni B, and Mini E (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861-879.
102. O'Hare T, Eide CA, and Deininger M W N (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242-2249. (Pubitemid 47523141)
103. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, and Schellens JH (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40.
104. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, and Eguchi K et al. (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64:98-104.
105. Özvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K, and Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485-1495. (Pubitemid 38668306)
106. Özvegy-Laczka C, Köblös G, Sarkadi B, and Váradi A (2005) Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 1668:53-63. (Pubitemid 40164733)
107. Özvegy-Laczka C, Laczkó R, Hegedus C, Litman T, Várady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, and Váradi A et al. (2008) Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem 283:26059-26070.
108. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14. (Pubitemid 40128022)
109. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo (4, 5-b) pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152. (Pubitemid 40096463)
110. Peng KC, Cluzeaud F, Bens M, Duong Van Huyen JP, Wioland MA, Lacave R, and Vandewalle A (1999) Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 47:757-768.
111. Pick A, Müller H, and Wiese M (2008) Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 16:8224-8236.
112. Plasschaert SL, van der Kolk DM, De Bont ES, Kamps WA, Morisaki K, Bates SE, Scheffer GL, Scheper RJ, Vellenga E, and De Vries EG (2003) The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 9:5171-5177. (Pubitemid 37413566)
113. Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, Tarasova N, Robey RW, and Bates SE (2010) Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry 49:2235-2245.
114. Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, and Dean M et al. (2006) Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Biochemistry 45:5251-5260.
115. Polgar O, Robey RW, and Bates SE (2008) ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4:1-15.
116. Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, and Bates SE (2004) Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43:9448-9456. (Pubitemid 38955477)
117. Pradhan M, Bembinster LA, Baumgarten SC, and Frasor J (2010) Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFkB cooperativity at adjacent response elements. J Biol Chem 285:31100-31106.
118. Raaijmakers MH, De Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ, Scheffer GL, De Witte TJ, and Raymakers RA (2005) Breast cancer resistance protein in drug resistance of primitive CD34138-cells in acute myeloid leukemia. Clin Cancer Res 11:2436-2444. (Pubitemid 40490205)
119. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, and Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850-5858. (Pubitemid 29006428)
120. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50. (Pubitemid 30058728)
121. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978. (Pubitemid 37533279)
122. Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, and Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridolresistant human breast cancer cells. Clin Cancer Res 7:145-152. (Pubitemid 32110217)
123. Robey RW, Polgar O, Deeken J, To KW, and Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39-57. (Pubitemid 46452182)
124. Robey RW, Steadman K, Polgar O, and Bates SE (2005) ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther 4:187-194. (Pubitemid 41351317)
125. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246. (Pubitemid 38235589)
126. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61:3-13.
127. Rosenberg MF, Bikadi Z, Chan J, Liu X, Ni Z, Cai X, Ford RC, and Mao Q (2010) The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 18:482-493.
128. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, and Doyle LA (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429-433. (Pubitemid 29128278)
129. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, and Taylor CG (2001) Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115:257-262. (Pubitemid 34203486)
130. Sarkadi B, Özvegy-Laczka C, Német K, and Váradi A (2004) ABCG2 - a transporter for all seasons. FEBS Lett 567:116-120. (Pubitemid 38686433)
131. Sauerbrey A, Sell W, Steinbach D, Voigt A, and Zintl F (2002) Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118:147-150. (Pubitemid 34779530)
132. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, De Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, and van der Valk P, et al. (2000) Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60:2589-2593. (Pubitemid 30318229)
133. Seldin DW (2004) The development of the clearance concept. J Nephrol 17:166-171. (Pubitemid 38444644)
134. Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:105-127. (Pubitemid 351560534)
135. Shi Z, Parmar S, Peng X-X, Shen T, Robey RW, Bates SE, Fu L-W, Shao Y, Chen Y-M, and Zang F et al. (2009) The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep 21:483-489.
136. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim I-W, Bates SE, Peng X, Abraham I, and Ambudkar SV, et al. (2011) Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 71:3029-3041.
137. Shigeta J, Katayama K, Mitsuhashi J, Noguchi K, and Sugimoto Y (2010) BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization. Cancer Sci 101:1813-1821.
138. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, and Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396-401. (Pubitemid 39551674)
139. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, and McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C. A genotype. Clin Pharmacol Ther 76:38-44. (Pubitemid 38844732)
140. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, and Gelderblom H (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4:650-658.
141. Stam RW, Van Den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, and Pieters R (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18:78-83. (Pubitemid 38159442)
142. Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, Cygalova L, Nachtigal P, and Fendrich Z (2006) Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 319:53-62. (Pubitemid 44455110)
143. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447.
144. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, and Baer MR (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia 18:1252-1257. (Pubitemid 39023136)
145. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649. (Pubitemid 36830322)
146. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
147. Tiwari AK and Chen Z-S (2013) Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. Front Pharmacol 4:82.
148. Uggla B, Ståhl E, Wågsäter D, Paul C, Karlsson MG, Sirsjö A, and Tidefelt U (2005) BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 29:141-146. (Pubitemid 39647507)
149. Van den Heuvel-Eibrink M, Wiemer E, Prins A, Meijerink J, Vossebeld P, Van der Holt B, Pieters R, and Sonneveld P (2002) Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16:833-839. (Pubitemid 34537555)
150. Vander Borght S, Libbrecht L, Katoonizadeh A, van Pelt J, Cassiman D, Nevens F, Van Lommel A, Petersen BE, Fevery J, and Jansen PL et al. (2006) Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem 54:1051-1059. (Pubitemid 44298592)
151. van der Kolk DM, Vellenga E, Scheffer GL, Müller M, Bates SE, Scheper RJ, and De Vries EG (2002) Expression and activity of breast cancer resistance protein (BCRP) in De novo and relapsed acute myeloid leukemia. Blood 99:3763-3770. (Pubitemid 34534549)
152. van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der Maas M, Weijers G, Scheffer GL, Allen JD, Scheper RJ, and van Loevezijn A (2003) Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88:134-147. (Pubitemid 37101491)
153. van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, and Schinkel AH (2007) Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 27:1247-1253. (Pubitemid 46239808)
154. van Loevezijn A, Allen JD, Schinkel AH, and Koomen G-J (2001) Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett 11:29-32. (Pubitemid 32006117)
155. Vaughan AM and Oram JF (2005) ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 280:30150-30157. (Pubitemid 41216193)
156. Velamakanni S, Janvilisri T, Shahi S, and van Veen HW (2008) A functional steroidbinding element in an ATP-binding cassette multidrug transporter. Mol Pharmacol 73:12-17. (Pubitemid 350294192)
157. Visvader JE and Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768.
158. Vlaming M L H, Lagas JS, and Schinkel AH (2009) Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 61:14-25.
159. Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A, and Ishikawa T (2006) Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol 5:205-222. (Pubitemid 43843831)
160. Wakabayashi K, Nakagawa H, Tamura A, Koshiba S, Hoshijima K, Komada M, and Ishikawa T (2007) Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J Biol Chem 282:27841-27846. (Pubitemid 47529524)
161. Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD, and Mao Q (2008) Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol 73:845-854. (Pubitemid 351397889)
162. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S-i, and Baba M (2004) Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 68:1363-1370. (Pubitemid 39179395)
163. Ward A, Reyes CL, Yu J, Roth CB, and Chang G (2007) Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc Natl Acad Sci USA 104:19005-19010.
164. Wilkinson GR and Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
165. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, and Fazli L et al. (2008) The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283:3349-3356.
166. Xu J, Peng H, Chen Q, Liu Y, Dong Z, and Zhang J-T (2007) Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res 67:4373-4381. (Pubitemid 46815086)
167. Yang C-H, Huang C-J, Yang C-S, Chu Y-C, Cheng A-L, Whang-Peng J, and Yang P-C (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65:6943-6949. (Pubitemid 41060734)
168. Yang CJ, Horton JK, Cowan KH, and Schneider E (1995) Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55:4004-4009.
169. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, and Soda H et al. (2004) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 110:921-927. (Pubitemid 38758521)
170. Zhang S, Yang X, Coburn RA, and Morris ME (2005) Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70:627-639. (Pubitemid 40978553)
171. Zhang Y, Wang H, Unadkat JD, and Mao Q (2007) Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab Dispos 35:2154-2158. (Pubitemid 350146200)
172. Zhou S, Schuetz JD, Bunting KD, Colapietro A-M, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, and Nakauchi H et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034. (Pubitemid 32937383)